BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21822687)

  • 21. Carboxyterminal propeptide of type I procollagen in osteomalacia.
    Li F; Iqbal J; Wassif W; Kaddam I; Moniz C
    Calcif Tissue Int; 1994 Aug; 55(2):90-3. PubMed ID: 7953986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rickets guidance: part II-management.
    Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
    Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
    Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
    Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
    Xiao L; Homer-Bouthiette C; Hurley MM
    J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
    Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
    J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Levels of Serum Sclerostin in Adult Patients With Tumor-Induced Osteomalacia Compared With X-linked Hypophosphatemia.
    Ni X; Zhang Q; Li X; Pang Q; Gong Y; Wang O; Li M; Xing X; Jiang Y; Xia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):e361-e371. PubMed ID: 34363479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
    Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
    Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels].
    de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P
    Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH).
    Fratzl-Zelman N; Gamsjaeger S; Blouin S; Kocijan R; Plasenzotti P; Rokidi S; Nawrot-Wawrzyniak K; Roetzer K; Uyanik G; Haeusler G; Shane E; Cohen A; Klaushofer K; Paschalis EP; Roschger P; Fratzl P; Zwerina J; Zwettler E
    J Struct Biol; 2020 Sep; 211(3):107556. PubMed ID: 32619592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissociation of clinical, laboratory, and bone biopsy findings in adult X-linked hypophosphatemia: a case report.
    Kocijan R; Mindler GT; Hartmann MA; Kraus DA; Raimann A; Zwerina J
    Wien Med Wochenschr; 2023 Oct; 173(13-14):339-345. PubMed ID: 36695943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
    Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
    N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypophosphatemic rickets and osteomalacia.
    de Menezes Filho H; de Castro LC; Damiani D
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):802-13. PubMed ID: 17117305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
    Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
    Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.